A kind of advanced prostate cancer is castration-resistant prostate cancer (CRPC). Hormonal therapy, which includes therapies that reduce testosterone, no longer works to treat the cancer in CRPC. The use of hormone treatment, sometimes referred to as androgen deprivation therapy (ADT), drastically lowers the body's testosterone levels.
The testosterone levels have been decreased to the point that they are similar to those of men who have had their testicles surgically removed.
Global castration-resistant prostate cancer treatment Market research offers a detailed and comprehensive analysis of the global market, with a particular focus on future projections. The report is structured into various segments, each analysing the factors and events likely to impact the market in the upcoming years.
Furthermore, the report includes Porter's Five Forces analysis that evaluates the competitive forces in the global castration-resistant prostate cancer treatment Market, such as the bargaining power of customers and suppliers, the threat of new entrants, the threat of substitutes, and the level of competition among existing competitors.
Additionally, the report offers insights into the market dynamics, such as market drivers, challenges, and opportunities.
Unleashing the Market Dynamics:
Novel castration-resistant prostate cancer treatments will fuel market expansion:
Castrate-resistant prostate cancer (CRPC) arises when prostate cancer resists androgen deprivation therapy (ADT), which suppresses androgens like testosterone that drive cancer development. CRPCs make for 10%–20% of prostate malignancies. Only 16% of CRPCs are identified before metastasis (nmCRPC). After CRPC develops, stronger androgen-reducers may help, but cancer ultimately defies them. Even in CRPC, androgen receptor (AR) signaling drives tumour development. Enzalutamide, a second-generation AR antagonist, is the standard CRPC treatment.
These medicines also block AR nuclear translocation and decrease androgen-dependent genes downstream due to their increased affinity for the AR binding domain and no agonist effect. Enzalutamide increased OS and PFS in chemotherapy-pretreated and chemotherapy-naive mCRPC patients compared to placebo in phase-3 studies.
Apalutamide and darolutamide have also been approved by the US FDA for nmCRPC after phase-3 studies showed prolonged metastasis-free survival. So, innovative therapeutics have helped drive market expansion in the future years.
Side Effects associated with hormone therapy for the treatment:
Orchiectomy (surgical castration) is a kind of surgery that functions as hormone treatment, according to the American Cancer Society. Some of the side effects of the therapy include decreased or absent sexual desire, impotence, shrinkage of the testicles and penis, hot flashes that may get better or stop over time, breast tenderness and tissue growth (gynecomastia), anaemia (low red blood cell counts), diminished mental sharpness, loss of sex drive, and loss of appetite. Some of the above-mentioned negative effects are expected to impede market expansion.
Major Players:
Major key players in the castration-resistant prostate cancer treatment market are
- Active Biotech AB
- Northwest Biotherapeutics
- Millennium Pharmaceuticals
DataM Intelligence’s report on the castration-resistant prostate cancer treatment market provides insights into the key drivers, challenges, top trends, and opportunities in the market. It also provides a geographical analysis and competitive landscape, which will paint a clear picture of the current market scenario.
To gain deeper insights into the castration-resistant prostate cancer treatment market and stay ahead of the competition, request a sample report from DataM Intelligence today.
